Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2017, Article ID 8412508, 13 pages
https://doi.org/10.1155/2017/8412508
Review Article

Natural Products as Adjunctive Treatment for Pancreatic Cancer: Recent Trends and Advancements

1Department of Oncology, Shanghai 9th People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
2Department of Chemical Biology, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ, USA
3Department of Cardiothoracic Surgery, Weihai Municipal Hospital, Weihai, Shandong, China
4Department of Pathology, Weihai Municipal Hospital, Weihai, Shandong, China
5Department of Internal Medicine, University of Missouri Hospital and Clinics, Columbia, MO, USA
6Allan H. Conney Laboratory for Anticancer Research, School of Chemical Engineering and Light Industry, Guangdong University of Technology, Guangzhou, China

Correspondence should be addressed to Qingxi Yue; nc.ca.sbis@euyxq and Xi Zheng; ude.sregtur.ycamrahp@gnehzix

Received 3 August 2016; Revised 9 December 2016; Accepted 27 December 2016; Published 23 January 2017

Academic Editor: Li Jiao

Copyright © 2017 Qingxi Yue et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. A. Torre, F. Bray, R. L. Siegel, J. Ferlay, J. Lortet-Tieulent, and A. Jemal, “Global cancer statistics, 2012,” CA: A Cancer Journal for Clinicians, vol. 65, no. 2, pp. 87–108, 2015. View at Publisher · View at Google Scholar · View at Scopus
  2. R. L. Siegel, K. D. Miller, and A. Jemal, “Cancer statistics, 2016,” CA Cancer Journal for Clinicians, vol. 66, no. 1, pp. 7–30, 2016. View at Publisher · View at Google Scholar · View at Scopus
  3. W. Chen, R. Zheng, P. D. Baade et al., “Cancer statistics in China, 2015,” CA Cancer Journal for Clinicians, vol. 66, no. 2, pp. 115–132, 2016. View at Publisher · View at Google Scholar · View at Scopus
  4. A. S. Paulson, H. S. Tran Cao, M. A. Tempero, and A. M. Lowy, “Therapeutic advances in pancreatic cancer,” Gastroenterology, vol. 144, no. 6, pp. 1316–1326, 2013. View at Publisher · View at Google Scholar · View at Scopus
  5. L. Perkhofer, T. J. Ettrich, and T. Seufferlein, “Pancreatic cancer: progress in systemic therapy,” Gastrointestinal Tumors, vol. 1, no. 4, pp. 167–179, 2014. View at Publisher · View at Google Scholar
  6. S. D. Stan, S. V. Singh, and R. E. Brand, “Chemoprevention strategies for pancreatic cancer,” Nature Reviews Gastroenterology and Hepatology, vol. 7, no. 6, pp. 347–356, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. J.-E. Ying, L.-M. Zhu, and B.-X. Liu, “Developments in metastatic pancreatic cancer: is gemcitabine still the standard?” World Journal of Gastroenterology, vol. 18, no. 8, pp. 736–745, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Akinleye, C. Iragavarapu, M. Furqan, S. Cang, and D. Liu, “Novel agents for advanced pancreatic cancer,” Oncotarget, vol. 6, no. 37, pp. 39521–39537, 2015. View at Publisher · View at Google Scholar · View at Scopus
  9. S. Perwez Hussain, “Pancreatic cancer: current progress and future challenges,” International Journal of Biological Sciences, vol. 12, no. 3, pp. 270–272, 2016. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Mohammed, N. B. Janakiram, S. Pant, and C. V. Rao, “Molecular targeted intervention for pancreatic cancer,” Cancers, vol. 7, no. 3, pp. 1499–1542, 2015. View at Publisher · View at Google Scholar · View at Scopus
  11. L. Li and P. S. Leung, “Use of herbal medicines and natural products: an alternative approach to overcoming the apoptotic resistance of pancreatic cancer,” International Journal of Biochemistry and Cell Biology, vol. 53, pp. 224–236, 2014. View at Publisher · View at Google Scholar · View at Scopus
  12. B. Li, R. Gan, Q. Yang et al., “Chinese herbal medicines as an adjunctive therapy for unresectable pancreatic cancer: a systematic review and meta-analysis,” Evidence-Based Complementary and Alternative Medicine, vol. 2015, Article ID 350730, 15 pages, 2015. View at Publisher · View at Google Scholar · View at Scopus
  13. S. Banerjee, Z. Wang, D. Kong, and F. H. Sarkar, “3,3′-Diindolylmethane enhances chemosensitivity of multiple chemotherapeutic agents in pancreatic cancer,” Cancer Research, vol. 69, no. 13, pp. 5592–5600, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. S. Banerjee, A. O. Kaseb, Z. Wang et al., “Antitumor activity of gemcitabine and oxaliplatin is augmented by thymoquinone in pancreatic cancer,” Cancer Research, vol. 69, no. 13, pp. 5575–5583, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. N. H. Thoennissen, G. B. Iwanski, N. B. Doan et al., “Cucurbitacin B induces apoptosis by inhibition of the JAK/STAT pathway and potentiates antiproliferative effects of gemcitabine on pancreatic cancer cells,” Cancer Research, vol. 69, no. 14, pp. 5876–5884, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. G. Kallifatidis, S. Labsch, V. Rausch et al., “Sulforaphane increases drug-mediated cytotoxicity toward cancer stem-like cells of pancreas and prostate,” Molecular Therapy, vol. 19, no. 1, pp. 188–195, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. B. K. Holcomb, M. T. Yip-Schneider, J. A. Waters, J. D. Beane, P. A. Crooks, and C. M. Schmidt, “Dimethylamino parthenolide enhances the inhibitory effects of gemcitabine in human pancreatic cancer cells,” Journal of Gastrointestinal Surgery, vol. 16, no. 7, pp. 1333–1340, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. M. T. Yip-Schneider, H. Wu, K. Stantz, N. Agaram, P. A. Crooks, and C. M. Schmidt, “Dimethylaminoparthenolide and gemcitabine: a survival study using a genetically engineered mouse model of pancreatic cancer,” BMC Cancer, vol. 13, article no. 194, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. X. Zheng, X.-X. Cui, Z. Gao et al., “Effects of 12-O-tetradecanoylphorbol-13-acetate in combination with gemcitabine on Panc-1 pancreatic cancer cells cultured in vitro or Panc-1 tumors grown in immunodeficient mice,” International Journal of Oncology, vol. 41, no. 6, pp. 2269–2275, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. D.-W. Ahn, J. K. Seo, S. H. Lee et al., “Enhanced antitumor effect of combination therapy with gemcitabine and guggulsterone in pancreatic cancer,” Pancreas, vol. 41, no. 7, pp. 1048–1057, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. H. Akasaka, R. Sasaki, K. Yoshida et al., “Monogalactosyl diacylglycerol, a replicative DNA polymerase inhibitor, from spinach enhances the anti-cell proliferation effect of gemcitabine in human pancreatic cancer cells,” Biochimica et Biophysica Acta, vol. 1830, no. 3, pp. 2517–2525, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. D. Yeo, N. Huynh, J. A. Beutler et al., “Glaucarubinone and gemcitabine synergistically reduce pancreatic cancer growth via down-regulation of P21-activated kinases,” Cancer Letters, vol. 346, no. 2, pp. 264–272, 2014. View at Publisher · View at Google Scholar · View at Scopus
  23. G.-G. Mu, L.-L. Zhang, H.-Y. Li, Y. Liao, and H.-G. Yu, “Thymoquinone pretreatment overcomes the insensitivity and potentiates the antitumor effect of gemcitabine through abrogation of notch1, PI3K/Akt/mTOR regulated signaling pathways in pancreatic cancer,” Digestive Diseases and Sciences, vol. 60, no. 4, pp. 1067–1080, 2015. View at Publisher · View at Google Scholar · View at Scopus
  24. T. Namba, R. Kodama, S. Moritomo, T. Hoshino, and T. Mizushima, “Zidovudine, an anti-viral drug, resensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine by inhibition of the Akt-GSK3β-Snail pathway,” Cell Death and Disease, vol. 6, no. 6, Article ID e1795, 2015. View at Publisher · View at Google Scholar
  25. Y. Wang, X. Wu, Y. Zhou, H. Jiang, S. Pan, and B. Sun, “Piperlongumine suppresses growth and sensitizes pancreatic tumors to gemcitabine in a xenograft mouse model by modulating the NF-kappa B pathway,” Cancer Prevention Research, vol. 9, no. 3, pp. 234–244, 2016. View at Publisher · View at Google Scholar · View at Scopus
  26. Y.-W. Wang, S.-J. Wang, Y.-N. Zhou, S.-H. Pan, and B. Sun, “Escin augments the efficacy of gemcitabine through down-regulation of nuclear factor-κB and nuclear factor-κB-regulated gene products in pancreatic cancer both in vitro and in vivo,” Journal of Cancer Research and Clinical Oncology, vol. 138, no. 5, pp. 785–797, 2012. View at Publisher · View at Google Scholar · View at Scopus
  27. A. Rimmon, A. Vexler, L. Berkovich, G. Earon, I. Ron, and S. Lev-Ari, “Escin chemosensitizes human pancreatic cancer cells and inhibits the nuclear factor-kappaB signaling pathway,” Biochemistry Research International, vol. 2013, Article ID 251752, 9 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  28. X.-Y. Huang, H.-C. Wang, Z. Yuan et al., “Gemcitabine combined with gum mastic causes potent growth inhibition and apoptosis of pancreatic cancer cells,” Acta Pharmacologica Sinica, vol. 31, no. 6, pp. 741–745, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. A. B. Kunnumakkara, B. Sung, J. Ravindran et al., “Zyflamend suppresses growth and sensitizes human pancreatic tumors to gemcitabine in an orthotopic mouse model through modulation of multiple targets,” International Journal of Cancer, vol. 131, no. 3, pp. E292–E303, 2012. View at Publisher · View at Google Scholar · View at Scopus
  30. M. Hattori, K. Kawakami, M. Akimoto, K. Takenaga, J. Suzumiya, and Y. Honma, “Antitumor effect of Japanese apricot extract (MK615) on human cancer cells in vitro and in vivo through a reactive oxygen species-dependent mechanism,” Tumori, vol. 99, no. 2, pp. 239–248, 2013. View at Publisher · View at Google Scholar · View at Scopus
  31. J. Yu, J. Drisko, and Q. Chen, “Inhibition of pancreatic cancer and potentiation of gemcitabine effects by the extract of Pao Pereira,” Oncology Reports, vol. 30, no. 1, pp. 149–156, 2013. View at Publisher · View at Google Scholar · View at Scopus
  32. Y. Xu, F. Zhu, S. Xu, and L. Liu, “Anti-tumor effect of the extract from Qingyihuaji formula on pancreatic cancer by down-regulating Notch-4 and Jagged-1,” Journal of Traditional Chinese Medicine, vol. 35, no. 1, pp. 77–83, 2015. View at Publisher · View at Google Scholar · View at Scopus
  33. Y. Pan, P. Rhea, L. Tan et al., “PBI-05204, a supercritical CO2 extract of Nerium oleander, inhibits growth of human pancreatic cancer via targeting the PI3K/mTOR pathway,” Investigational New Drugs, vol. 33, no. 2, pp. 271–279, 2015. View at Publisher · View at Google Scholar · View at Scopus
  34. J. Tai, S. S. C. Cheung, D. Ou, G. L. Warnock, and D. Hasman, “Antiproliferation activity of Devil's club (Oplopanax horridus) and anticancer agents on human pancreatic cancer multicellular spheroids,” Phytomedicine, vol. 21, no. 4, pp. 506–514, 2014. View at Publisher · View at Google Scholar · View at Scopus
  35. S. S. C. Cheung, J. Tai, D. Hasman, D. Ou, and G. L. Warnock, “Inhibition of human pancreatic cancer cell proliferation by Devil's club oplopanax horridus and its polyacetylene bioactive compound,” Nutrition and Cancer, vol. 67, no. 6, pp. 954–964, 2015. View at Publisher · View at Google Scholar · View at Scopus
  36. G. E. Avila, X. Zheng, X. X. Cui et al., “Inhibitory effects of 12-O-tetradecanoylphorbol-13-acetate alone or in combination with all-trans retinoic acid on the growth of cultured human pancreas cancer cells and pancreas tumor xenografts in immunodeficient mice,” Journal of Pharmacology and Experimental Therapeutics, vol. 315, no. 1, pp. 170–187, 2005. View at Publisher · View at Google Scholar · View at Scopus
  37. H. Huang, K. Cao, S. Malik et al., “Combination of 12-O-tetradecanoylphorbol-13-Acetate with diethyldithiocarbamate markedly inhibits pancreatic cancer cell growth in 3D culture and in immunodeficient mice,” International Journal of Molecular Medicine, vol. 35, no. 6, pp. 1617–1624, 2015. View at Publisher · View at Google Scholar · View at Scopus
  38. M. T. Yip-Schneider, H. Nakshatri, C. J. Sweeney, M. S. Marshall, E. A. Wiebke, and C. M. Schmidt, “Parthenolide and sulindac cooperate to mediate growth suppression and inhibit the nuclear factor-κB pathway in pancreatic carcinoma cells,” Molecular Cancer Therapeutics, vol. 4, no. 4, pp. 587–594, 2005. View at Publisher · View at Google Scholar · View at Scopus
  39. M. T. Yip-Schneider, H. Wu, V. Njoku et al., “Effect of celecoxib and the novel anti-cancer agent, dimethylamino- parthenolide, in a developmental model of pancreatic cancer,” Pancreas, vol. 37, no. 3, pp. e45–e53, 2008. View at Publisher · View at Google Scholar · View at Scopus
  40. S.-W. Yang, W. Wang, X.-Y. Xie, W.-P. Zhu, and F.-Q. Li, “In vitro synergistic cytotoxic effect of triptolide combined with hydroxycamptothecin on pancreatic cancer cells,” American Journal of Chinese Medicine, vol. 39, no. 1, pp. 121–134, 2011. View at Publisher · View at Google Scholar · View at Scopus
  41. Y. Li, T. Zhang, S. J. Schwartz, and D. Sun, “Sulforaphane potentiates the efficacy of 17-allylamino 17- demethoxygeldanamycin against pancreatic cancer through enhanced abrogation of Hsp90 chaperone function,” Nutrition and Cancer, vol. 63, no. 7, pp. 1151–1159, 2011. View at Publisher · View at Google Scholar · View at Scopus
  42. Y. Yuan, A. J. Tang, A. B. Castoreno et al., “Gossypol and an HMT G9a inhibitor act in synergy to induce cell death in pancreatic cancer cells,” Cell Death & Disease, vol. 4, article no. e690, 2013. View at Google Scholar · View at Scopus
  43. R. E. Schwarz, C. A. Donohue, D. Sadava, and S. E. Kane, “Pancreatic cancer in vitro toxicity mediated by Chinese herbs SPES and PC-SPES: implications for monotherapy and combination treatment,” Cancer Letters, vol. 189, no. 1, pp. 59–68, 2003. View at Publisher · View at Google Scholar · View at Scopus
  44. L. Berkovich, G. Earon, I. Ron, A. Rimmon, A. Vexler, and S. Lev-Ari, “Moringa Oleifera aqueous leaf extract down-regulates nuclear factor-kappaB and increases cytotoxic effect of chemotherapy in pancreatic cancer cells,” BMC Complementary and Alternative Medicine, vol. 13, article 212, 2013. View at Publisher · View at Google Scholar · View at Scopus
  45. R. M. Mohammad, S. Wang, S. Banerjee, X. Wu, J. Chen, and F. H. Sarkar, “Nonpeptidic small-molecule inhibitor of Bcl-2 and Bcl-XL, (−)-gossypol, enhances biological effect of genistein against BxPC-3 human pancreatic cancer cell line,” Pancreas, vol. 31, no. 4, pp. 317–324, 2005. View at Publisher · View at Google Scholar · View at Scopus
  46. R. K. Srivastava, S. N. Tang, W. Zhu, D. Meeker, and S. Shankar, “Sulforaphane synergizes with quercetin to inhibit self-renewal capacity of pancreatic cancer stem cells,” Frontiers in Bioscience, vol. 3, pp. 515–528, 2011. View at Google Scholar
  47. J. Ding, G. Polier, R. Köhler, M. Giaisi, P. H. Krammer, and M. Li-Weber, “Wogonin and related natural flavones overcome tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) protein resistance of tumors by down-regulation of c-FLIP protein and up-regulation of TRAIL receptor 2 expression,” The Journal of Biological Chemistry, vol. 287, no. 1, pp. 641–649, 2012. View at Publisher · View at Google Scholar · View at Scopus
  48. W. Yue, X. Zheng, Y. Lin et al., “Metformin combined with aspirin significantly inhibit pancreatic cancer cell growth in vitro and in vivo by suppressing antiapoptotic proteins Mcl-1 and Bcl-2,” Oncotarget, vol. 6, no. 25, pp. 21208–21224, 2015. View at Publisher · View at Google Scholar · View at Scopus
  49. T. C. McMorris, M. J. Kelner, W. Wang, J. Yu, L. A. Estes, and R. Taetle, “(Hydroxymethyl)acylfulvene: an illudin derivative with superior antitumor properties,” Journal of Natural Products, vol. 59, no. 9, pp. 896–899, 1996. View at Publisher · View at Google Scholar · View at Scopus
  50. S. E. Witta, G. S. Eckhardt, M. Rothenberg et al., “A phase I combination trial of irofulven and gemcitabine in patients with advanced solid malignancies,” Proc ASCO, vol. 22, article 138, 2003. View at Google Scholar
  51. E. S. Van Laar, S. Roth, S. Weitman, J. R. MacDonald, and S. J. Waters, “Activity of irofulven against human pancreatic carcinoma cell lines in vitro and in vivo,” Anticancer Research, vol. 24, no. 1, pp. 59–65, 2004. View at Google Scholar · View at Scopus
  52. S. M. Kupchan, D. R. Streelman, and A. T. Sneden, “Psorospermin, a new antileukemic xanthone from psorospermum febrifugum,” Journal of Natural Products (Lloydia), vol. 43, no. 2, pp. 296–301, 1980. View at Publisher · View at Google Scholar · View at Scopus
  53. J. M. Cassady, W. M. Baird, and C.-J. Chang, “Natural products as a source of potential cancer chemotherapeutic and chemopreventive agents,” Journal of Natural Products, vol. 53, no. 1, pp. 23–41, 1990. View at Publisher · View at Google Scholar · View at Scopus
  54. I. M. Fellows, M. Schwaebe, T. S. Dexheimer et al., “Determination of the importance of the stereochemistry of psorospermin in topoisomerase II-induced alkylation of DNA and in vitro and in vivo biological activity,” Molecular Cancer Therapeutics, vol. 4, no. 11, pp. 1729–1739, 2005. View at Publisher · View at Google Scholar · View at Scopus
  55. M. T. Yip-Schneider, H. Wu, R. H. Hruban, A. M. Lowy, P. A. Crooks, and C. M. Schmidt, “Efficacy of dimethylaminoparthenolide and sulindac in combination with gemcitabine in a genetically engineered mouse model of pancreatic cancer,” Pancreas, vol. 42, no. 1, pp. 160–167, 2013. View at Publisher · View at Google Scholar · View at Scopus
  56. C. J. Sinal and F. J. Gonzalez, “Guggulsterone: an old approach to a new problem,” Trends in Endocrinology and Metabolism, vol. 13, no. 7, pp. 275–276, 2002. View at Publisher · View at Google Scholar · View at Scopus
  57. J. R. Hanson, “The development of strategies for terpenoid structure determination,” Natural Product Reports, vol. 18, no. 6, pp. 607–617, 2001. View at Publisher · View at Google Scholar · View at Scopus
  58. T. Issat, D. Nowis, J. Bil, M. Winiarska, M. Jakobisiak, and J. Golab, “Antitumor effects of the combination of cholesterol reducing drugs,” Oncology Reports, vol. 26, no. 1, pp. 169–176, 2011. View at Publisher · View at Google Scholar · View at Scopus
  59. M. A. Reis, A. Paterna, A. Mónico, J. Molnar, H. Lage, and M.-J. U. Ferreira, “Diterpenes from Euphorbia piscatoria: synergistic interaction of lathyranes with doxorubicin on resistant cancer cells,” Planta Medica, vol. 80, no. 18, pp. 1739–1745, 2014. View at Publisher · View at Google Scholar · View at Scopus
  60. B. Hauns, B. Häring, S. Köhler, K. Mross, P. Robben-Bathe, and C. Unger, “Phase II study with 5-fluorouracil and ginkgo biloba extract (GBE 761 ONC) in patients with pancreatic cancer,” Arzneimittel-Forschung, vol. 49, no. 12, pp. 1030–1034, 1999. View at Google Scholar · View at Scopus
  61. G. Bar-Sela, R. Epelbaum, and M. Schaffer, “Curcumin as an anti-cancer agent: review of the gap between basic and clinical applications,” Current Medicinal Chemistry, vol. 17, no. 3, pp. 190–197, 2010. View at Publisher · View at Google Scholar · View at Scopus
  62. R. Epelbaum, M. Schaffer, B. Vizel, V. Badmaev, and G. Bar-Sela, “Curcumin and gemcitabine in patients with advanced pancreatic cancer,” Nutrition and Cancer, vol. 62, no. 8, pp. 1137–1141, 2010. View at Publisher · View at Google Scholar · View at Scopus
  63. H. Matthes, W. E. Friedel, P. R. Bock, and K. S. Zänker, “Molecular mistletoe therapy: friend or foe in established antitumor protocols? a multicenter, controlled, retrospective pharmaco-epidemiological study in pancreas cancer,” Current Molecular Medicine, vol. 10, no. 4, pp. 430–439, 2010. View at Publisher · View at Google Scholar · View at Scopus
  64. J.-M. Löhr, M. Karimi, B. Omazic et al., “A phase I dose escalation trial of AXP107-11, a novel multi-component crystalline form of genistein, in combination with gemcitabine in chemotherapy-naive patients with unresectable pancreatic cancer,” Pancreatology, vol. 16, no. 4, pp. 640–645, 2016. View at Publisher · View at Google Scholar · View at Scopus
  65. M. W. Saif, F. Lansigan, S. Ruta et al., “Phase I study of the botanical formulation PHY906 with capecitabine in advanced pancreatic and other gastrointestinal malignancies,” Phytomedicine, vol. 17, no. 3-4, pp. 161–169, 2010. View at Publisher · View at Google Scholar · View at Scopus
  66. M. W. Saif, J. Li, L. Lamb et al., “First-in-human phase II trial of the botanical formulation PHY906 with capecitabine as second-line therapy in patients with advanced pancreatic cancer,” Cancer Chemotherapy and Pharmacology, vol. 73, no. 2, pp. 373–380, 2014. View at Publisher · View at Google Scholar · View at Scopus
  67. S. T. Chen, J. Dou, R. Temple, R. Agarwal, K.-M. Wu, and S. Walker, “New therapies from old medicines,” Nature Biotechnology, vol. 26, no. 10, pp. 1077–1083, 2008. View at Publisher · View at Google Scholar · View at Scopus